News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NovaDel Pharma (NVD) Announces Termination of License Agreements for Ondansetron Oral Spray Product


1/23/2012 6:07:48 AM

BRIDGEWATER, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (OTCBB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced the termination of certain license agreements with Talon Therapeutics, Inc. and Par Pharmaceutical Companies, Inc., relating to the development and commercialization of the Company’s ondansetron HCl oral spray product, effective as of January 16, 2012.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES